Drug Profile
PG 102 - Helixmith
Alternative Names: PG102-HelixmithLatest Information Update: 08 Aug 2019
Price :
$50
*
At a glance
- Originator ViroMed Co Ltd
- Developer Helixmith; SBI Biotech
- Class Plant allergy immunotherapies
- Mechanism of Action Helper-inducer T-lymphocyte inhibitors; IgE receptor antagonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic contact dermatitis
- No development reported Allergic rhinitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-rhinitis in Japan
- 17 Jun 2015 PG 102 is still in phase-II development for Allergic diseases in South Korea
- 17 Jun 2010 Phase-II clinical trials in Allergic contact dermatitis in South Korea (unspecified route)